Dry AMD is manifested in 80–85% of all cases, but treatment options are available only to patients with wet AMD and do not address disease causes, but rely on the inhibition of vascular endothelial growth factor (VEGF) by antiangiogenic agents [6]. Here, VEGFA is linked to wet macular degeneration.